S1331 Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis

Authors :: David Zahrieh
Priyanka Kanth
Elena M. Stoffel
Carol A. Burke
Rohit Das
Michelle Westover
Gary Della'Zanna
Luz Rodriguez
Paul J. Limburg
Nathan R. Foster
Ellen Richmond
Ryan McMurray
Marcia Cruz-Correa
N. Jewel Samadder
Eva Szabo
Eduardo Vilar Sanchez
Source :: American Journal of Gastroenterology. 116:S614-S614
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.

Subjects :: medicine.medical_specialty
Hepatology
business.industry
Internal medicine
Gastroenterology
Medicine
Erlotinib
Dosing
business
medicine.disease
Familial adenomatous polyposis
medicine.drug

Full Text Access

Tools